Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Insel Gruppe AG, University Hospital Bern120 enrolled

Overview

Transcatheter aortic valve implantation (TAVI) is a well-established alternative to surgical aortic valve replacement for the treatment of patients with symptomatic severe aortic stenosis. While peri-procedural complications such as stroke, vascular complications and bleeding have substantially declined with the refinement of transcatheter valves and increasing experience, new-onset atrial fibrillation (NOAF) or atrioventricular conduction disturbances continue to occur in almost half of all patients. Colchicine is a well-known substance that has been approved for the treatment of acute gout flares and familial Mediterranean fever in many countries. Colchicine has proven safe and effective in the prevention of atrial fibrillation after cardiac surgery. The anti-inflammatory effects of colchicine may mitigate the occurrence of atrioventricular conduction disturbances and thus the need for the implantation of a permanent pacemaker post transcatheter aortic valve implantation. The objective of the Co-STAR-Trial is to investigate the efficacy of colchicine for the prevention of new-onset atrial fibrillation and conduction disturbances requiring the implantation of a permanent pacemaker in patients undergoing transcatheter aortic valve implantation. Co-STAR is an investigator-initiated, randomized, double blind, placebo-controlled trial. A total of 200 patients referred for treatment of symptomatic severe aortic stenosis and selected to undergo TAVI will be randomized in a 1:1 ratio to the treatment with Colchicine or placebo for 30 days post transcatheter aortic valve implantation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

120

Conditions

Eligibility

Sex: ALLMin age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥ 65 years 2. Symptomatic severe aortic stenosis defined by an aortic valve area (AVA) ≤1.0 cm2 or an AVA indexed to body surface area \<0.6cm2/m2 3. Selected to undergo transfemoral TAVI based on heart team decision Exclusion Criteria: 1. Life expectancy \<1 year irrespective of valvular heart disease 2. Kidney disease with a creatinine clearance ≤30 ml/min 3. Known severe liver disease 4. Known neuromuscular disease 5. Clinically significant anaemia with haemoglobin \<80g/L 6. Known inflammatory bowel disease or chronic diarrhea 7. Known ongoing bacterial infection 8. Known galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption 9. Current treatment with colchicine, steroids or biologicals for any indication 10. Concomitant intake of Cyclosporine, Amiodarone, Clarithromycin, Erythromycin, Omeprazole, Verapamil or other strong inhibitors of CYP3A4 or P-Glycoprotein 11. Concomitant intake of Carbamazepin, Phenobarbital, Phenytoin, Rifampicin or other strong inductors of CYP3A4 and P-Glycoprotein 12. Permanent pacemaker or implantable cardioverter defibrillator 13. History of atrial fibrillation 14. Absence of sinus rhythm on hospital admission 15. Planned non-cardiac surgery within 30 days 16. Known intolerance to colchicine 17. Inability to provide written informed consent 18. Known or suspected non-compliance, drug or alcohol abuse 19. Participation in another clinical trial with an active intervention 20. Any other planned cardiac intervention performed in the 7 days before TAVI, concomitantly with TAVI or in the 30 days after TAVI except for percutaneous coronary interventions.

Outcomes

Primary Outcomes

Incidence rate of the composite of new onset atrial fibrillation or occurrence of conduction disturbances requiring the implantation of a permanent pacemaker

Assessed based on extended rhythm monitoring performed until 7 days post-discharge as well as clinically or incidentally captured episodes of NOAF captured during routine care thereafter. NOAF is defined as at least one episode of atrial fibrillation with a duration \>30s.

Time frame: 30 days

Secondary Outcomes

Single components of primary composite endpoint

Including predefine sensitivity analysis using the alternative definition of NOAF: At least one episode of atrial fibrillation with a duration \>6 min.

Time frame: 30 days and 1 year

The incidence of conductance disturbances

New or worsened first-degree atrioventricular (AV) block, second-degree AV block (Mobitz I or Mobitz II), high-grade atrioventricular block, third-degree AV block, right bundle branch block, left bundle branch block, left anterior fascicular block, left posterior fascicular block, intraventricular conduction delay

Time frame: 30 days, 1 year

The predictors of conductance disturbances

Time frame: 30 days, 1 year

The incidence of new arrhythmias resulting in hemodynamic instability or requiring therapy

Defined as electrical/medical cardioversion or initiation of a new medication e.g. oral anticoagulation, rhythm, or rate controlling therapy

Time frame: 30 days, 1 year

Inflammatory marker levels

IL-6, IL-8, TNF-alpha, IL-1β, CRP, high-sensitivity CRP

Time frame: at day 1

The proportion of patients with at least one prosthetic leaflet with > 50% motion reduction or with at least one prosthetic leaflet with thickening

Based on a study-specific cardiac computed tomography angiography

Time frame: 30 days

The proportion of prosthetic leaflets with > 50% motion reduction or leaflet thickening

Based on a study-specific cardiac computed tomography angiography

Time frame: 30 days

The incidences of major clinical adverse events

All-cause mortality, stroke, systemic embolism, myocardial infarction, infections, clinical valve thrombosis

Time frame: 30 days, 1 year

Colchicine for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes